Bronconex Acticap

Ülke: Yeni Zelanda

Dil: İngilizce

Kaynak: Medsafe (Medicines Safety Authority)

Aktif bileşen:

Mometasone furoate 400ug (anhydrous)

Mevcut itibaren:

Organon (New Zealand) Limited

INN (International Adı):

Mometasone furoate 400 µg (anhydrous)

Doz:

400 mcg/dose

Farmasötik formu:

Powder for inhalation

Kompozisyon:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Paketteki üniteler:

Inhaler, metered, DPI, (sample), 14 dose units

Sınıf:

Prescription

Reçete türü:

Prescription

Tarafından üretildi:

MSD International GmbH (Singapore Branch)

Terapötik endikasyonlar:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Ürün özeti:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Yetkilendirme tarihi:

2000-12-05